Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

Abstract Background For patients starting treatment for depression, current guidelines recommend titrating the antidepressant dosage to the maximum of the licenced range if tolerated. When patients do not achieve remission within several weeks, recommendations include adding or switching to another...

Full description

Bibliographic Details
Main Authors: Tadashi Kato, Toshi A. Furukawa, Akio Mantani, Ken’ichi Kurata, Hajime Kubouchi, Susumu Hirota, Hirotoshi Sato, Kazuyuki Sugishita, Bun Chino, Kahori Itoh, Yoshio Ikeda, Yoshihiro Shinagawa, Masaki Kondo, Yasumasa Okamoto, Hirokazu Fujita, Motomu Suga, Shingo Yasumoto, Naohisa Tsujino, Takeshi Inoue, Noboru Fujise, Tatsuo Akechi, Mitsuhiko Yamada, Shinji Shimodera, Norio Watanabe, Masatoshi Inagaki, Kazuhira Miki, Yusuke Ogawa, Nozomi Takeshima, Yu Hayasaka, Aran Tajika, Kiyomi Shinohara, Naohiro Yonemoto, Shiro Tanaka, Qi Zhou, Gordon H. Guyatt, for the SUN☺D Investigators
Format: Article
Language:English
Published: BMC 2018-07-01
Series:BMC Medicine
Subjects:
Major depressive disorder
Antidepressive agents: first-line treatment
Second-line treatment
Randomised controlled trial
Online Access:http://link.springer.com/article/10.1186/s12916-018-1096-5

Internet

http://link.springer.com/article/10.1186/s12916-018-1096-5

Similar Items